Navigation Links
Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
Date:7/14/2008

FREMONT, Calif., July 14 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that it has engaged ThinkPanmure LLC., a global, growth-company investment bank, to assist the Company in identifying and evaluating strategic alternatives intended to enhance the potential of the Company's proteomic tests (OVA1(TM) and VASCLIR(TM)) and pipeline of proprietary biomarkers to maximize stockholder value. No assurances can be given that this evaluation will lead to any specific action or transaction.

"We continuously evaluate our strategic options to identify and develop prospects for maximizing value for all stockholders and look forward to working with ThinkPanmure in this regard," said Gail Page, President and Chief Executive Officer of Vermillion. "While reviewing the various alternatives, we will continue to advance our commercialization strategies, namely building marketplace awareness for our women's health, oncology, and cardiac programs which include the OVA1(TM) and VASCLIR(TM) tests."

About ThinkPanmure LLC

ThinkPanmure LLC is a research-centric institutional investment bank focused on the growth economy. ThinkPanmure LLC is dedicated to providing strategic advice, in-depth research coverage and capital to corporate clients and institutional investors interested in the knowledge economy's key growth verticals: consumer business services, healthcare, media, and technology. For more information about ThinkPanmure LLC, please visit http://www.thinkpanmure.com. Member NASD and SIPC.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including the risks and uncertainties discussed in Vermillion's Form 10-K for the year ended December 31, 2007, and Vermillion's periodic reports on Form 10-Q and Form 8-K. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. In particular, there can be no assurance that Vermillion will enter into a strategic transaction, that, if any transaction is commenced, it will be completed or as to the value that any such transaction might have for Vermillion's stockholders. Forward-looking statements cannot be guaranteed and actual results may differ materially from Vermillion's current expectations. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
2. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
3. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
4. Vermillion Announces Appointment of John Hamilton to Board of Directors
5. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
6. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
7. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. Vermillion Receives NASDAQ Notice of Non-Compliance
11. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Mich. , May 26, 2016  Agriculture nutrients ... Des Moines, Iowa is running their ... Lake Erie and coastal regions ... key to preventing this widespread issue. NECi ... Upper Peninsula, developed a new, easy to ...
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several ... Inc. at the City of Knowledge in Panama, a 6 year-old Duchenne’s ... the US earlier this year following FDA approval of a second application for ...
(Date:5/26/2016)... ... 26, 2016 , ... FireflySci has been manufacturing quartz and ... over the globe. Their cute firefly logo has been spreading to more and ... spectrophotometer calibration standards that never require recalibration. These revolutionary standards have changed ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):